Search Contract Opportunities

Notice of Intent to Sole Source: non-GMP scale up synthesis of (4-(1-(3-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4-((3-fluorobenzyl)oxy)-3-methoxyphenyl)methanone

ID: 75N95024Q00492 • Type: Special Notice • Match:  85%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Draft a response outline indicating that my company is also capable of performing this sole source work
Do the documents mention an incumbent contractor?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

INTRODUCTION

THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to A1 BioChem Labs LLC 5598 Marvin K. Moss Lane, Wilmington, NC 28409 USA for non-GMP scale up synthesis of (4-(1-(3-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4-((3-fluorobenzyl)oxy)-3-methoxyphenyl)methanone

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS

The intended procurement is classified under NAICS code 541380 Testing Laboratories and Services with a Size Standard of $16.50.

REGULATORY AUTHORITY

This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures. Contracts awarded using FAR Part 13 Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6 Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization).

The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2022-08 dated October 22, 2022.

DESCRIPTION OF REQUIREMENT

PURPOSE AND OBJECTIVES:

This requisition is for the non-GMP scale-up synthesis of (4-(1-(3-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4-((3-fluorobenzyl)oxy)-3-methoxyphenyl)methanone in a 250 g quantity with >99% purity, as characterized by LCMS, NMR, and other analytical techniques. The amount of material is crucial for performing toxicity and efficacy studies in different animal models to further facilitate in developing as a non-opioid pain medication.

Provide all the data generated including raw data and reports. The test materials are not transferable or shall not be used for any other purposes

The contractor will provide the 250 g material in >99 % purity, data analysis and report for the contents of this statement of work either electronically or as a written report.

ESTIMATED PERIOD OF PERFORMANCE:

4 weeks ARO

CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION

The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Cellecta, Inc. of Mountain View, CA is the only vendor in the marketplace that can provide the services required by NIDA .

The intended source is:

A1 BioChem Labs LLC

5598 Marvin K. Moss Lane

Wilmington, NC 28409 USA

CLOSING STATEMENT

THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by the closing date and time of this announcement and must reference the solicitation number, 75N95024Q00492. Responses must be submitted electronically to Kaitlyn Landi, Contract Specialist, at kaitlyn.landi@nih.gov and KJ Shaikh, Contracting Officer, at kj.shaikh@nih.gov. U.S. Mail and fax responses will not be accepted.

Background
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is responsible for advancing knowledge about drug abuse and addiction. The agency's mission includes conducting and supporting medical research to improve health outcomes.

This contract aims to facilitate the development of a non-opioid pain medication by procuring a specific compound necessary for toxicity and efficacy studies in animal models.

Work Details
The contractor will perform the non-GMP scale-up synthesis of a specified compound in a quantity of 250 grams with a purity greater than 99%, as verified by LCMS, NMR, and other analytical techniques.

The contractor is required to provide all generated data, including raw data and reports, ensuring that the test materials are not transferable or used for any other purposes. The final deliverables include the synthesized material along with data analysis and a report, which can be submitted electronically or as a written document.

Period of Performance
The contract will be performed over a period of four weeks after receipt of the contract award.

Place of Performance
Wilmington, NC 28409 USA

Overview

Response Deadline
Aug. 10, 2024, 12:00 p.m. EDT Past Due
Posted
Aug. 5, 2024, 9:16 a.m. EDT
Set Aside
None
Place of Performance
Not Provided
Source

Current SBA Size Standard
$19 Million
Pricing
Likely Fixed Price
Est. Level of Competition
Sole Source
Est. Value Range
Experimental
<$250,000 (solicitation indicates Simplified Acquisition Procedures, which in most cases, applies to contracts expected to be less than $250K in value)
On 8/5/24 National Institute on Drug Abuse issued Special Notice 75N95024Q00492 for Notice of Intent to Sole Source: non-GMP scale up synthesis of (4-(1-(3-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)(4-((3-fluorobenzyl)oxy)-3-methoxyphenyl)methanone due 8/10/24.
Primary Contact
Name
Kaitlyn Landi   Profile
Phone
(301) 827-1804

Documents

Posted documents for Special Notice 75N95024Q00492

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Incumbent or Similar Awards

Contracts Similar to Special Notice 75N95024Q00492

Potential Bidders and Partners

Awardees that have won contracts similar to Special Notice 75N95024Q00492

Similar Active Opportunities

Open contract opportunities similar to Special Notice 75N95024Q00492

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > NATIONAL INSTITUTES OF HEALTH > NATIONAL INSTITUTES OF HEALTH NIDA
FPDS Organization Code
7529-75N950
Source Organization Code
100189048
Last Updated
Aug. 25, 2024
Last Updated By
kaitlyn.landi@nih.gov
Archive Date
Aug. 25, 2024